跳至主要内容
临床试验/NL-OMON34180
NL-OMON34180撤回不适用

Tissue impedance measurement (TIM) as an index of oesophageal mucosal integrity - Tissue impedance measurement (TIM): index of oesophageal mucosal integrity

niversitair Medisch Centrum Utrecht0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Females and males between 18 and 45 yrs of age
  • * No significant clinical pathology or history of heartburn, regurgitation, dysphagia or chest pain or acid
  • suppressive therapy or any other major abdominal complaints in the last year. No history of signs of pathological
  • changes of the oesophageal mucosa visible with conventional endoscopic examination
  • * BMI < 30 or a body weight < 100 kg
  • * No clinically significant illness within the 2 weeks prior to inclusion or a suspected/manifest infection according
  • to WHO risk categories 2, 3 or 4, as judged by the investigator
  • * No history of clinically significant illness, cardiovascular, respiratory, renal, hepatic, neurological, mental or
  • gastrointestinal, as judged by the investigator
  • * Normal ECG as judged by the investigator
  • * Absence of severe allergy/hypersensitivity or symptoms/signs of ongoing allergy/hypersensivity
  • * No history of excessive bleeding or suspected coagulopathy
  • * No prior surgery of the upper GI tract except over sewing of an ulcer
  • * No use of PPI, H2 receptor antagonists, pro-kinetic drugs or need for any medication for gastroesophageal
  • reflux disease
  • * No history of drug addiction (including cannabinoids), alcohol abuse or other circumstances which in the investigator*s judgment may compromise the subject*s participation
  • * No involvement in the planning and conduct of the study
  • * No pregnancy or lactation
  • * Signed informed consent to participate in the study

排除标准

  • * Clinically significant illness within the 2 weeks prior to inclusion or a suspected/manifest infection according to
  • WHO risk categories 2, 3 or 4, as judged by the investigator
  • * Absence of informed consent
  • * BMI *30 or a body weight * 100 kg
  • * History of clinically significant illness, cardiovascular, respiratory, renal, hepatic, neurological, mental or
  • gastrointestinal, as judged by the investigator
  • * Abnormal ECG as judged by the investigator
  • * History of severe allergy/hypersensitivity or symptoms/signs of ongoing allergy/hypersensivity
  • * History of excessive bleeding or suspected coagulopathy
  • * Prior surgery of the upper GI tract except over sewing of an ulcer
  • * Use of PPI, H2 receptor antagonists, pro-kinetic drugs or need for any medication for gastroesophageal reflux
  • * History of drug addiction (including cannabinoids), alcohol abuse or other circumstances which in the
  • investigator*s judgment may compromise the subject*s participation
  • * Inability to comply with study procedures
  • * Involvement in the planning and conduct of the study
  • * Previous enrolment in the present study.
  • * Pregnancy or lactation

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验